Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are life-threatening diseases with a high burden of symptoms. Although depression, anxiety, and reduced health related quality of life (HRQOL) have also been reported, a comparative analysis which explores these traits and their underlying factors was lacking.
A retrospective analysis of depression, anxiety, and health related QOL was conducted using a Hospital anxiety and depression scale (HADS) as well as the SF-36 HRQOL questionnaire. Results from these tools were compared with haemodynamic and functional parameters in 70 PAH and 23 CTEPH outpatients from a German tertiary care center specializing in pulmonary hypertension.
Although HRQOL was reduced in both cohorts of patients, individuals diagnosed with CTEPH scored lower in nearly all SF-36 parameters. Significance was noted in both “mental health” (p = 0.01) and “mental component summary score” (MCS) (p = 0.02). Depression was also more frequent in patients with CTEPH (56%) than in patients with PAH (30%), (p = 0.03). Overall, depression and anxiety correlated with most SF-36 scales in both PAH and CTEPH. In CTEPH, depression also correlated with the Borg Dyspnea Scale (r = 0.44, p = 0.01). These patients also had significantly lower pCO2 levels than the PAH cohort reflecting more severe ventilation/perfusion mismatch. All other haemodynamic and functional parameters did not differ across the groups.
While both cohorts of patients suffer from a reduced HRQOL as well as depression and anxiety, decreases in mental health parameters are more pronounced in the CTEPH cohort. This suggests a strong effort to improve early detection, especially in dyspneic patients with classical risk factors for CTEPH and PAH and argues for mental illness interventions alongside routine clinical care provided to patients diagnosed with PAH or CTEPH.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Galie N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67–119
Hoeper MM, Bogaard HJ, Condliffe R et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42–D50
Hoeper MM, Huscher D, Ghofrani HA et al (2013) Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168(2):871–880
Humbert M, Sitbon O, Chaouat A et al (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173(9):1023–1030
Held M, Grun M, Holl R et al (2014) Chronic thromboembolic pulmonary hypertension: time delay from onset of symptoms to diagnosis and clinical condition at diagnosis. Dtsch Med Wochenschr 139(33):1647–1652
Lewczuk J, Piszko P, Jagas J et al (2001) Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 119(3):818–823
Wilkens H, Grimminger F, Hoeper M et al (2010) Burden of pulmonary arterial hypertension in Germany. Respir Med 104(6):902–910
Rich JD, Rich S (2014) Clinical diagnosis of pulmonary hypertension. Circulation 130(20):1820–1830
Rich S, Dantzker DR, Ayres SM et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107(2):216–223
Mayer E, Jenkins D, Lindner J et al (2011) Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 141(3):702–710
Badesch DB, Raskob GE, Elliott CG et al (2010) Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137(2):376–387
Löwe B, Gräfe K, Ufer C et al (2004) Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 66(6):831–836
Halank M, Einsle F, Lehman S et al (2013) Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung 191(4):337–343
Harzheim D, Klose H, Pinado FP et al (2013) Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res 14:104
Shafazand S, Goldstein MK, Doyle RL et al (2004) Health-related quality of life in patients with pulmonary arterial hypertension. Chest 126(5):1452–1459
Taichman DB, Shin J, Hud L et al (2005) Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 6:92
McCollister DH, Beutz M, McLaughlin V et al (2010) Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics 51(4):339–339 e8
Looper KJ, Pierre A, Dunkley DM et al (2009) Depressive symptoms in relation to physical functioning in pulmonary hypertension. J Psychosom Res 66(3):221–225
Roman A, Barbera JA, Castillo MJ et al (2013) Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Arch Bronconeumol 49(5):181–188
Cenedese E, Speich R, Dorschner L et al (2006) Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 28(4):808–815
White J, Hopkins RO, Glissmeyer EW et al (2006) Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension. Respir Res 7:55
Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30(20):S2493–S2537
Remillard C, Yuan J (2008) Characterization of hemodynamics in patients with idiopathic and thromboembolic pulmonary hypertension. Clin Med Insights 2:59–68
Baptista R, Meireles J, Agapito A et al (2013) Pulmonary hypertension in Portugal: first data from a nationwide registry. Biomed Res Int 2013:489574
Mueller-Mottet S, Stricker H, Domenighetti G et al (2015) Long-term data from the Swiss pulmonary hypertension registry. Respiration 89(2):127–140
Parikh KS, Rajagopal S, Arges K et al (2015) Use of outcome measures in pulmonary hypertension clinical trials. Am Heart J 170(3):419–429
Strange G, Keogh AM, Williams TJ et al (2008) Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology 13(5):674–682
Sastry BK, Narasimhan C, Reddy NK et al (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43(7):1149–1153
Gihl A (2010) Health-related quality of life in pulmonary arterial hypertension. Adv Pulm Hypertens 8(4):215–222
Ghofrani HA, D’Armini AM, Grimminger F et al (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369(4):319–329
Mathai SC, Ghofrani HA, Mayer E et al (2016) Quality of life in patients with chronic thromboembolic pulmonary hypertension. Eur Respir J 48(2):526–537
Urushibara T, Tanabe N, Suda R et al (2015) Effects of surgical and medical treatment on quality of life for patients with chronic thromboembolic pulmonary hypertension. Circ J 79(12):2696–2702
Kirson NY, Birnbaum HG, Ivanova JI et al (2011) Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin 27(9):1763–1768
Rosenkranz S, Behr J, Ewert R et al (2011) Right heart catheterization in pulmonary hypertension. Dtsch Med Wochenschr 136(50):2601–2616 quiz 2617-20
Rudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23(7):685–713 quiz 786-8
Society AT (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117
American Thoracic S und American College of Chest P (2003) ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167(2):211–277
Meyer FJ, Borst MM, Buschmann HC et al (2013) Exercise testing in respiratory medicine. Pneumologie 67(1):16–34
Borg GA (1982) Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14(5):377–381
Borg G (1998) Borg’s perceived exertion and pain scales. Human Kinetics, Champaign
Snaith RP, Zigmond AS, Herrmann-Lingen C et al (1995) Hospital anxiety and depression scale: deutsche Version; HADS-D; ein Fragebogen zur Erfassung von Angst und Depressivität in der somatischen Medizin; Testdokumentation und Handanweisung. 1. Aufl (ed), Bern [u.a.]: Huber. 43, III S
Bullinger M, Kirchberger I (1998) Fragebogen zum Gesundheitszustand: SF-36; Handanweisung. Göttingen [u.a.]: Hogrefe. 155 Seiten
Bjelland I, Dahl AA, Haug TT et al (2002) The validity of the Hospital Anxiety and Depression Scale. an updated literature review. J Psychosom Res 52(2):69–77
Katon WJ (2003) Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 54(3):216–226
Maurer J, Rebbapragada V, Borson S et al (2008) Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 134(4 Suppl):43S–56S
Yohannes AM, Willgoss TG, Baldwin RC et al (2010) Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 25(12):1209–1221
Jiang W, Kuchibhatla M, Cuffe MS et al (2004) Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation 110(22):3452–3456
Ng TP, Niti M, Tan WC et al (2007) Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 167(1):60–67
Coultas DB, Edwards DW, Barnett B et al (2007) Predictors of depressive symptoms in patients with COPD and health impact. COPD 4(1):23–28
Paukert AL, LeMaire A, Cully JA (2009) Predictors of depressive symptoms in older veterans with heart failure. Aging Ment Health 13(4):601–610
Devins GM, Bezjak A, Mah K et al (2006) Context moderates illness-induced lifestyle disruptions across life domains: a test of the illness intrusiveness theoretical framework in six common cancers. Psychooncology 15(3):221–233
Thakur ER, Sansgiry S, Petersen NJ et al (2017) Cognitive and perceptual factors, not disease severity, are linked with anxiety in COPD: results from a cross-sectional study. Int J Behav Med. doi:10.1007/s12529-017-9663-2
Gomberg-Maitland M, Thenappan T, Rizvi K et al (2008) United States validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR). J Heart Lung Transplant 27(1):124–130
Twiss J, McKenna S, Ganderton L et al (2013) Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension. BMC Pulm Med 13:45
Hoeper MM, Pletz MW, Golpon H et al (2007) Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 29(5):944–950
Liu WH, Luo Q, Liu ZH et al (2014) Differences in exercise capacity in patients with chronic left heart failure and chronic right heart failure. Heart Lung Circ 23(11):1036–1040
Dumitrescu D, Oudiz RJ, Karpouzas G et al (2010) Developing pulmonary vasculopathy in systemic sclerosis, detected with non-invasive cardiopulmonary exercise testing. PLoS ONE 5(12):e14293
Held M, Grün M, Holl R et al (2014) Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography. Respiration 87(5):379–387
Scheidl SJ, Englisch C, Kovacs G et al (2012) Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. Eur Respir J 39(1):119–124
Pepke-Zaba J, Delcroix M, Lang I et al (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124(18):1973–1981
Parshall MB, Schwartzstein RM, Adams L et al (2012) An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 185(4):435–452
Bass JJ (1990) Dyspnea. In: Walker HK, Hall WD, Hurst JW (eds) Clinical methods: the history, physical, and laboratory examinations. Butterworths, Boston
Smoller JW, Pollack MH, Otto MW et al (1996) Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med 154(1):6–17
Lansing RW, Gracely RH, Banzett RB (2009) The multiple dimensions of dyspnea: review and hypotheses. Respir Physiol Neurobiol 167(1):53–60
Riera HS, Rubio TM, Ruiz FO et al (2001) Inspiratory muscle training in patients with COPD: effect on dyspnea, exercise performance, and quality of life. Chest 120(3):748–756
Smith EL, Hann DM, Ahles TA et al (2001) Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer. J Pain Symptom Manag 21(4):323–329
de Voogd JN, Sanderman R, Postema K et al (2011) Relationship between anxiety and dyspnea on exertion in patients with chronic obstructive pulmonary disease. Anxiety Stress Coping 24(4):439–449
There was no funding of the presented work.
Conflict of interest
Dr. Elena Pfeuffer has nothing to disclose. Dr. Krannich has nothing to disclose. Dr. Halank reports personal fees for lectures and consultations and travel/accommodation, meeting expenses from Actelion, AstraZeneca, Bayer, BERLIN CHEMIE, GILEAD, GSK, Lilly, MSD, Novartis, OMT, and Pfizer, outside the submitted work. Prof. Dr. Wilkens reports grants and personal fees from Actelion, personal fees from Bayer Vital, Glaxo Smith Kline, Pfizer, Biotest, Boehringer Ingelheim, and Roche outside the submitted work. Philipp Kolb has nothing to disclose. Prof. Dr. Jany has nothing to disclose. Dr. Held reports grants from Actelion, honoraria for lectures from Actelion, Bayer HealthCare, Berlin Chemie, Boehringer Ingelheim, GSK, Novartis, Pfizer, honoraria for advisory board activities from Actelion, Bayer HealthCare, GSK, MSD, and partizipation in clinical trials of Actelion, Bayer HealthCare, GSK, Pfizer, United Therapeutics, outside the submitted work.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Research Involving Human and Animal Rights
This article does not contain any studies with animals performed by any of the authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Pfeuffer, E., Krannich, H., Halank, M. et al. Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH. Lung 195, 759–768 (2017). https://doi.org/10.1007/s00408-017-0052-z
- Quality of life
- Mental health
- Pulmonary hypertension